The NAUTIKA1 trial is an ongoing, phase II trial that will look at the efficacy of targeted therapies in the neoadjuvant setting for patients with stage IB-IIIB NSCLC with ALK, ROS1, NTRK, BRAF, RET, KRAS G12C mutations (53). Here, BRAF is linked to non-small cell lung carcinoma.